APA (7th ed.) Citation

Chatterjee, P., Canale, V., King, S. J., Shawki, A., Lei, H., Haddad, M., . . . McCole, D. F. (2024, September 28). The JAK inhibitor, Tofacitinib, Corrects the Overexpression of CEACAM6 and Limits Susceptibility to AIEC Caused by Reduced Activity of the IBD Associated Gene, PTPN2. medRxiv : the preprint server for health sciences. https://doi.org/10.1101/2024.09.26.24314341

Chicago Style (17th ed.) Citation

Chatterjee, Pritha, et al. "The JAK Inhibitor, Tofacitinib, Corrects the Overexpression of CEACAM6 and Limits Susceptibility to AIEC Caused by Reduced Activity of the IBD Associated Gene, PTPN2." MedRxiv : The Preprint Server for Health Sciences 28 Sep. 2024. https://doi.org/10.1101/2024.09.26.24314341.

MLA (9th ed.) Citation

Chatterjee, Pritha, et al. "The JAK Inhibitor, Tofacitinib, Corrects the Overexpression of CEACAM6 and Limits Susceptibility to AIEC Caused by Reduced Activity of the IBD Associated Gene, PTPN2." MedRxiv : The Preprint Server for Health Sciences, 28 Sep. 2024, https://doi.org/10.1101/2024.09.26.24314341.